4 (vs 6) Cycles of Adjuvant Chemo Sufficient for Early Breast Cancer

Share this article:
(ChemotherapyAdvisor) – No evidence was found that extending adjuvant doxorubicin and cyclophosphamide or single-agent paclitaxel from 4 to 6 cycles improves clinical outcome in women with resected primary breast cancer and 0 to 3 positive nodes, the Cancer and Leukemia Group B 40101 study reported in a rapid communication in the Journal of Clinical Oncology online July 23.

The study enrolled 3,171 women with operable breast cancer and 0 to 3 positive nodes (94% were node-negative and 6% had 1 to 3 positive nodes) between 2002 and 2008 and randomly assigned them to either 4 or 6 cycles of either doxorubicin and cyclophosphamide or paclitaxel. Patients were stratified by estrogen receptor/progesterone receptor, HER2, and menopausal status.

The 4-year relapse-free survival at a median follow-up of 5.3 years was 90.9% for 6 cycles and 91.8% for 4 cycles (adjusted HR 1.03 [95% CI, 0.84–1.28]; P=0.77). The 4-year overall survival was 95.3% for 6 cycles and 96.3% for 4 cycles [HR 1.12 [95% CI, 0.84 to 1.49]; P=0.44). No interaction was observed between treatment duration and chemotherapy regimen, estrogen-receptor/progesterone receptor, or HER2 status on relapse-free or overall survival.

This study demonstrates that “…patients can be spared longer and more toxic treatment with these regimens without fear of compromising breast cancer outcome,” Lawrence N. Shulman, MD, of the Dana-Farber Cancer Institute, Boston, MA, and colleagues concluded.

Abstract

Share this article:

Related Resources

You must be a registered member of Chemotherapy Advisor to post a comment.

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Breast Cancer

High-Fat Diet Ups Risk for Certain Breast Cancers

High-Fat Diet Ups Risk for Certain Breast Cancers

High intake of saturated fats is associated with increased risk of certain subtypes of breast cancer.

Palbociclib + Letrozole Prolongs Advanced Breast Cancer Survival

Palbociclib + Letrozole Prolongs Advanced Breast Cancer Survival

Pfizer announced results from the Phase 2 PALOMA-1 study that is investigating the use of palbociclib (PD-0332991) in combination with letrozole in patients with advanced breast cancer.

Minorities Hit Harder By Breast Cancer Costs

Minorities Hit Harder By Breast Cancer Costs

Racial and ethnic minority patients seem to be more vulnerable to breast cancer-related privations and financial decline.